Abstract
Nitrofurantoin lung toxicity was diagnosed among ten patients receiving 50 mg/day to prevent recurrent urinary tract infection. In six patients a symptomatic period of 3-36 months preceded the diagnosis. All but one patient, with irreversible lung injury at presentation recovered completely, five after drug discontinuation and four after steroids therapy. Large amount of data regarding unexpected, sometimes severe pulmonary toxicity during nitrofurantoin therapy should maintain a high index of suspicion for the drug usage among patients with non-resolving pulmonary symptoms. Alternatively, the use of other antimicrobial agents with a better risk-to-benefit ratio should be considered.
Keywords: Lung, nitrofurantoin, toxicity
Current Drug Safety
Title: Nitrofurantoin Pulmonary Toxicity: Neglected Threat
Volume: 5 Issue: 2
Author(s): Emilia Hardak, Gidon Berger, Norberto Krivoy, Anna Solomonov and Mordechai Yigla
Affiliation:
Keywords: Lung, nitrofurantoin, toxicity
Abstract: Nitrofurantoin lung toxicity was diagnosed among ten patients receiving 50 mg/day to prevent recurrent urinary tract infection. In six patients a symptomatic period of 3-36 months preceded the diagnosis. All but one patient, with irreversible lung injury at presentation recovered completely, five after drug discontinuation and four after steroids therapy. Large amount of data regarding unexpected, sometimes severe pulmonary toxicity during nitrofurantoin therapy should maintain a high index of suspicion for the drug usage among patients with non-resolving pulmonary symptoms. Alternatively, the use of other antimicrobial agents with a better risk-to-benefit ratio should be considered.
Export Options
About this article
Cite this article as:
Hardak Emilia, Berger Gidon, Krivoy Norberto, Solomonov Anna and Yigla Mordechai, Nitrofurantoin Pulmonary Toxicity: Neglected Threat, Current Drug Safety 2010; 5 (2) . https://dx.doi.org/10.2174/157488610790936169
DOI https://dx.doi.org/10.2174/157488610790936169 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Macrolides Allergy
Current Pharmaceutical Design Current Understanding and Unknown Aspects of the Treatment of Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Opportunities for Future Studies
Current Rheumatology Reviews Angiogenesis in Chronic Lymphocytic Leukemia
Current Angiogenesis (Discontinued) Meet Our Editorial Board Member:
Current Rheumatology Reviews Serum Adiponectin Levels in Patients with Familial Mediterranean Fever
Protein & Peptide Letters Gene Polymorphisms and Pharmacogenetics in Rheumatoid Arthritis
Current Genomics ATP-Sensitive Potassium Channel Modulators and Cardiac Arrhythmias: An Update
Current Pharmaceutical Design Crohns Targeted Therapy: Myth or Real Goal?
Current Drug Discovery Technologies Cellular Senescence in Cardiovascular Diseases: Potential Age-Related Mechanisms and Implications for Treatment
Current Pharmaceutical Design Design and Synthesis of Novel Coumarin Conjugated Acetamides as Promising Anticancer Agents: An <i>In Silico</i> and <i>In Vitro</i> Approach
Anti-Cancer Agents in Medicinal Chemistry Roles of Hematopoietic Stem and Progenitor Cells in Ischemic Cardiovascular Disease
Current Stem Cell Research & Therapy Skin Tests in the Diagnosis of Drug Hypersensitivity Reactions
Current Pharmaceutical Design Biomarkers Determining Cardiovascular Risk in Patients with Kidney Disease
Current Medicinal Chemistry Comparison of Clinical Features at the Onset of Takayasu’s Arteritis According to Age and Sex
Current Vascular Pharmacology The Phage Display Technique: Advantages and Recent Patents
Recent Patents on DNA & Gene Sequences Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients
Current Vascular Pharmacology A Study of the Relaxed Mechanisms Induced by Novokinin in the Isolated Porcine Coronary Artery Ring Segments
Protein & Peptide Letters Pro-Inflammatory Gene Variants in Myocardial Infarction and Longevity: Implications for Pharmacogenomics
Current Pharmaceutical Design Cyclophosphamide: Time to Say Goodnight and Goodbye?
Current Rheumatology Reviews Colchicine: An Old Wine in a New Bottle?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry